Neuroscience

Neuroscience Research Reagents

Neuroscience research spans neurodegenerative diseases (Alzheimer’s, Parkinson’s, ALS), neuropsychiatric disorders (depression, schizophrenia), and neurological injuries (stroke, TBI). Advances in biomarker discovery — from blood-based p-Tau and NfL assays to single-cell microglial profiling — are transforming diagnosis and drug development, driving demand for rigorously validated research reagents across these fields.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Neuroscience Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key neurodegenerative, neuroinflammatory, and neuropsychiatric research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

Neurodegeneration Markers — Key targets include amyloid-β, Tau/Phospho-Tau, α-synuclein, TDP-43, and huntingtin — aggregation-prone proteins driving Alzheimer’s, Parkinson’s, ALS, and Huntington’s disease. Antibodies and recombinant proteins support biomarker assay development, IHC pathology, and therapeutic target validation.
→ Browse neurodegeneration antibodies

Neuroinflammation & Microglia — TREM2, CD33, GFAP, and complement pathway proteins (C1q, C3) mediate microglial activation and astrocyte reactivity in neuroinflammation. Anti-TREM2 and anti-GFAP antibodies enable disease-associated microglia (DAM) profiling and reactive astrogliosis quantification.
→ Browse neuroinflammation antibodies & proteins

Neurotransmitter Receptors & Ion Channels — Glutamate receptors (NMDA, AMPA), GABA receptors, serotonin receptors (5-HT), and dopamine receptors are central to synaptic function and psychiatric disorder research. Antibodies support receptor expression profiling, electrophysiology studies, and drug target validation.

Neurofilament Light Chain (NfL) — Serum/CSF NfL is a validated pan-neurodegenerative biomarker for axonal damage severity and treatment response monitoring. Anti-NfL antibodies support ultrasensitive immunoassay development across multiple neurological conditions.

References

1. Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954-963. DOI

2. Hansson O, et al. The Alzheimer’s Association appropriate use recommendations for blood biomarkers. Alzheimers Dement. 2022;18(12):2669-2686. DOI

3. Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell. 2017;169(7):1276-1290. DOI

4. Khalil M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577-589. DOI